Biovica International
Biovica: A Further Take on a TK1 Pioneer (Redeye)

2020-06-30 07:20
Redeye views the completed analytical validation as a confirmation that the development of the DiviTum cancer diagnostic test is on track, with sights on a potential FDA clearance in the beginning of next year. We increase likelihood of approval. Also, we have reviewed our cost forecasts taking a more positive stance on margins in a partnering structure. We raise our base case to SEK 31 (24).

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Biovica International B - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -